Latest Updates
Thanks to everyone who joined the Nugevia™ Launch Party in New York City. What an unforgettable night!
We are honored to have gathered an extraordinary community of partners, peers, and supporters join us to witness the launch of Nugevia™. Among those present include our three distinguished ambassadors—Annika Sorenstam, Chris Webber, and Jean Fallacara—whose leadership across sports, science, and entrepreneurship embodies Nugevia’s mission: putting neuro health at the core of longevity.
This launch party is only the beginning. Powered by our patented JOTROL™ resveratrol platform, Nugevia™ expands our reach beyond therapeutics into consumer health, creating immediate impact today while advancing long-term innovation in CNS disorder treatment.
#Nugevia #Neuroprotection #HealthyAging #Neuroscience #Longevity #JUNS
We are honored to have gathered an extraordinary community of partners, peers, and supporters join us to witness the launch of Nugevia™. Among those present include our three distinguished ambassadors—Annika Sorenstam, Chris Webber, and Jean Fallacara—whose leadership across sports, science, and entrepreneurship embodies Nugevia’s mission: putting neuro health at the core of longevity.
This launch party is only the beginning. Powered by our patented JOTROL™ resveratrol platform, Nugevia™ expands our reach beyond therapeutics into consumer health, creating immediate impact today while advancing long-term innovation in CNS disorder treatment.
#Nugevia #Neuroprotection #HealthyAging #Neuroscience #Longevity #JUNS
Read more
Jupiter Neurosciences, Inc.
October 1, 2025
Exciting times ahead. While we are continuing our pursuit in finding an FDA approved treatment for Parkinson’s and Alzheimer’s we will soon launch products that we believe can work as prevention for these and other life threatening diseases. The goal is to shrink the gap between Longevity (how long you live) and how long in your life you will live an active lifestyle. The gap today is approximately 10 years and we want it as close to zero as possible.
Read more
Christer Rosén
March 5, 2025
Exciting times ahead. While we are continuing our pursuit in finding an FDA approved treatment for Parkinson’s and Alzheimer’s we will soon launch products that we believe can work as prevention for these and other life threatening diseases. The goal is to shrink the gap between Longevity (how long you live) and how long in your life you will live an active lifestyle. The gap today is approximately 10 years and we want it as close to zero as possible.
Read more
Jupiter Neurosciences, Inc.
March 5, 2025
Let’s stay healthy and live longer. I believe is a strong tool for your future
Christer Rosén
August 26, 2025
Read more
Jupiter Neurosciences, Inc.
August 26, 2025
Frustrating to deal with shortsellers but it’s all about delivery of fundamentals. We are committed to continue with that. Onwards and Upwards!!
Read more
Christer Rosén
July 11, 2025
Short sellers pushed our stock down to below the $1 mark. Part of being public, I guess. Remedy: Work harder and produce something that are a breakthrough for society which appeals to investors and your stock price will recover.
#Parkinsons #Longevity #JOTROL #Nugevia #BeutyFromWithin #mitochondria #antiinflammation #JUNS
https://lnkd.in/e9VNVaEW
#Parkinsons #Longevity #JOTROL #Nugevia #BeutyFromWithin #mitochondria #antiinflammation #JUNS
https://lnkd.in/e9VNVaEW
Read more
Jupiter Neurosciences, Inc.
July 11, 2025
Every movement has its pioneers — and in the world of biohacking and human performance, Jean Fallacara has long been one of them.
From founding ventures at the edge of biotechnology to being named Most Disruptive Entrepreneur (2023) and a Top Biohacking Influencer (2022), Jean has dedicated his career to one bold idea: pushing the limits of what it means to live, perform, and thrive.
That’s why we’re thrilled to welcome him as the third official brand ambassador for Nugevia™, our new consumer longevity line. Powered by our patented JOTROL™ platform, Nugevia™ unlocks the full potential of resveratrol to deliver real cellular resilience. It’s where clinical-grade science meets wellness innovation.
Jean put it best: “Nugevia™ is not just another supplement, it represents the convergence of clinical research, biotechnology, and wellness innovation. Whether you are an athlete, entrepreneur, or simply someone striving to optimize your quality of life, Nugevia™ provides the foundation for thriving in mind, body, and soul.”
Through this partnership, we are proud to bring visionary leaders and proven science together to address the growing demand for accessible longevity solutions.
🔗 Learn more: https://lnkd.in/ggaPveJd
#Nugevia #Neuroprotection #HealthyAging #Neuroscience #Longevity #JUNS
From founding ventures at the edge of biotechnology to being named Most Disruptive Entrepreneur (2023) and a Top Biohacking Influencer (2022), Jean has dedicated his career to one bold idea: pushing the limits of what it means to live, perform, and thrive.
That’s why we’re thrilled to welcome him as the third official brand ambassador for Nugevia™, our new consumer longevity line. Powered by our patented JOTROL™ platform, Nugevia™ unlocks the full potential of resveratrol to deliver real cellular resilience. It’s where clinical-grade science meets wellness innovation.
Jean put it best: “Nugevia™ is not just another supplement, it represents the convergence of clinical research, biotechnology, and wellness innovation. Whether you are an athlete, entrepreneur, or simply someone striving to optimize your quality of life, Nugevia™ provides the foundation for thriving in mind, body, and soul.”
Through this partnership, we are proud to bring visionary leaders and proven science together to address the growing demand for accessible longevity solutions.
🔗 Learn more: https://lnkd.in/ggaPveJd
#Nugevia #Neuroprotection #HealthyAging #Neuroscience #Longevity #JUNS
Read more
Jupiter Neurosciences, Inc.
September 16, 2025
Featured Company – Jupiter Neurosciences Inc.The team at B2i Digital welcomes Jupiter Neurosciences, Inc. (NASDAQ: JUNS) as a new Featured Company. Jupiter Neurosciences will be presenting at the 3rd Annual DealFlow Discovery Conference, a B2i Digital Featured Conference, on January 28-29, 2026 at The Borgata in Atlantic City, NJ. Christer Rosén, Founder, Chairman and CEO, will deliver the presentation and be available for one-on-one investor meetings. Conference details and registration are available at https://b2idigital.com/dealflow-discovery-conference-2026. A dedicated profile of the company will be available soon at https://b2idigital.com/featured-companies. Based in Jupiter, Florida, Jupiter Neurosciences is a clinical-stage pharmaceutical company built around JOTROL™, a patented resveratrol formulation that has demonstrated nine times greater bioavailability than earlier versions of the compound. The company operates a dual-path business model: advancing a therapeutic pipeline targeting neuroinflammation and CNS disorders while commercializing Nugevia™, a premium longevity supplement line using the same delivery technology.On the pharmaceutical side, the FDA cleared the company’s IND application in November 2025, authorizing a Phase 2a clinical trial in Parkinson’s disease with patient enrollment expected in early 2026. The company is also exploring potential applications in Alzheimer’s disease, Friedreich’s Ataxia, Mucopolysaccharidoses Type I, and MELAS. Research collaborations include partnerships with Harvard, Georgetown, MIT’s Picower Institute, and the University of Miami.Jupiter Neurosciences’s consumer business launched in 2025 with three Nugevia products (GLO, PWR, and MND), each targeting pillars of healthy aging: skin vitality, mitochondrial energy, and cognitive resilience. Brand ambassadors include golf icon Annika Sörenstam, NBA legend Chris Webber, and biohacker Jean Fallacara.Jupiter completed its IPO in December 2024 and has since secured access to up to $20 million in flexible capital through Yorkville Advisors to fund clinical development and commercial expansion. The company is led by Christer Rosén, Founder, Chairman and CEO; Alison D. Silva, President and CBO; Saleem Elmasri, CPA, CFO; Marshall Hayward, Ph.D., Co-Founder and CSO; Alexander Rosén, Co-Founder and CAO; Dr. Claes Wahlestedt, MD, Ph.D., Co-Founder and Consulting CMO; and Shaun P. Brothers, Ph.D., Co-Founder and Consulting Head of Scientific Research.To learn more about Jupiter Neurosciences, visit www.jupiterneurosciences.com. For investor inquiries, contact IR@jupiterneurosciences.com.Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.
Read more
B2i Digital, Inc.
January 26
Jupiter Neurosciences, Inc. (NASDAQ: JUNS) announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ consumer longevity product line.
Read more
The team at B2i Digital welcomes Jupiter Neurosciences, Inc. (NASDAQ: JUNS) as a new Featured Company. Jupiter Neurosciences will be presenting at the 3rd Annual DealFlow Discovery Conference, a B2i Digital Featured Conference, on January 28-29, 2026 at The Borgata in Atlantic City, NJ. Christer Rosén, Founder, Chairman and CEO, will deliver the presentation and be available for one-on-one investor meetings. Conference details and registration are available at https://b2idigital.com/dealflow-discovery-conference-2026.
A dedicated profile of the company will be available soon at https://b2idigital.com/featured-companies.
Based in Jupiter, Florida, Jupiter Neurosciences is a clinical-stage pharmaceutical company built around JOTROL™, a patented resveratrol formulation that has demonstrated nine times greater bioavailability than earlier versions of the compound. The company operates a dual-path business model: advancing a therapeutic pipeline targeting neuroinflammation and CNS disorders while commercializing Nugevia™, a premium longevity supplement line using the same delivery technology.
On the pharmaceutical side, the FDA cleared the company’s IND application in November 2025, authorizing a Phase 2a clinical trial in Parkinson’s disease with patient enrollment expected in early 2026. The company is also exploring potential applications in Alzheimer’s disease, Friedreich’s Ataxia, Mucopolysaccharidoses Type I, and MELAS. Research collaborations include partnerships with Harvard, Georgetown, MIT’s Picower Institute, and the University of Miami.
Jupiter Neurosciences’s consumer business launched in 2025 with three Nugevia products (GLO, PWR, and MND), each targeting pillars of healthy aging: skin vitality, mitochondrial energy, and cognitive resilience. Brand ambassadors include golf icon Annika Sörenstam, NBA legend Chris Webber, and biohacker Jean Fallacara.
Jupiter completed its IPO in December 2024 and has since secured access to up to $20 million in flexible capital through Yorkville Advisors to fund clinical development and commercial expansion.
A dedicated profile of the company will be available soon at https://b2idigital.com/featured-companies.
Based in Jupiter, Florida, Jupiter Neurosciences is a clinical-stage pharmaceutical company built around JOTROL™, a patented resveratrol formulation that has demonstrated nine times greater bioavailability than earlier versions of the compound. The company operates a dual-path business model: advancing a therapeutic pipeline targeting neuroinflammation and CNS disorders while commercializing Nugevia™, a premium longevity supplement line using the same delivery technology.
On the pharmaceutical side, the FDA cleared the company’s IND application in November 2025, authorizing a Phase 2a clinical trial in Parkinson’s disease with patient enrollment expected in early 2026. The company is also exploring potential applications in Alzheimer’s disease, Friedreich’s Ataxia, Mucopolysaccharidoses Type I, and MELAS. Research collaborations include partnerships with Harvard, Georgetown, MIT’s Picower Institute, and the University of Miami.
Jupiter Neurosciences’s consumer business launched in 2025 with three Nugevia products (GLO, PWR, and MND), each targeting pillars of healthy aging: skin vitality, mitochondrial energy, and cognitive resilience. Brand ambassadors include golf icon Annika Sörenstam, NBA legend Chris Webber, and biohacker Jean Fallacara.
Jupiter completed its IPO in December 2024 and has since secured access to up to $20 million in flexible capital through Yorkville Advisors to fund clinical development and commercial expansion.
Read more
@b2i_digital
January 26
We are very excited and proud to announce the launch of our Nugevia products via our website nugevia.com! Pre-Ordering is now available for our groundbreaking longevity supplements GLO, MND & PWR!
Read more
Jupiter Neurosciences, Inc.
August 26, 2025
Longevity isn’t just about adding years to life. It’s about living healthier throughout those years.
Improved healthspans promise enormous societal benefits. The McKinsey Health Institute finds that alleviating just half the burden of age-related diseases, which account for roughly one-third of the global disease burden, could prevent early deaths, reduce years spent in poor health, and generate up to $2 trillion in annual GDP uplift from an expanded workforce. A 2021 study published in Nature Aging also suggested that the economic value of adding one year of healthy life to everyone in the US could be as much as $38 trillion.
At Jupiter, we’re contributing to this movement through Nugevia™, powered by our patented JOTROL™ resveratrol platform. We are exploring how evidence-based innovation can help extend healthspan, bridging therapeutics and consumer health to create lasting value.
https://lnkd.in/eXYM2pJj
Discover our Nugevia™, the new generation pathway to longevity 👉https://nugevia.com/
#Nugevia #Neuroprotection #HealthyAging #Neuroscience #Longevity #JUNS
Improved healthspans promise enormous societal benefits. The McKinsey Health Institute finds that alleviating just half the burden of age-related diseases, which account for roughly one-third of the global disease burden, could prevent early deaths, reduce years spent in poor health, and generate up to $2 trillion in annual GDP uplift from an expanded workforce. A 2021 study published in Nature Aging also suggested that the economic value of adding one year of healthy life to everyone in the US could be as much as $38 trillion.
At Jupiter, we’re contributing to this movement through Nugevia™, powered by our patented JOTROL™ resveratrol platform. We are exploring how evidence-based innovation can help extend healthspan, bridging therapeutics and consumer health to create lasting value.
https://lnkd.in/eXYM2pJj
Discover our Nugevia™, the new generation pathway to longevity 👉https://nugevia.com/
#Nugevia #Neuroprotection #HealthyAging #Neuroscience #Longevity #JUNS
Read more
Jupiter Neurosciences, Inc.
September 10, 2025
